Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 20/20 | 0.57 |
| ▸ | CX3CR1 | P49238 | 4/20 | 0.54 |
| ▸ | HTR1B | P28222 | 1/20 | 0.47 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.42 |
| ▸ | CCR7 | P32248 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4221300 | 0.82 | CXCR2 (0.64) | CXCR2CX3CR1HTR1B | |
| SCHEMBL4229660 | 0.81 | CXCR2 (0.58) | CXCR2CX3CR1HTR1B | |
| SCHEMBL4229659 | 0.80 | CXCR2 (0.61) | CXCR2CX3CR1HTR1B | |
| SCHEMBL4230889 | 0.79 | CXCR2 (0.70) | CXCR2CX3CR1HTR1B | |
| SCHEMBL13243096 | 0.78 | CXCR2 (0.68) | CXCR2CX3CR1HTR1BCXCR1 | |
| SCHEMBL13140053 | 0.77 | CXCR2 (0.70) | CXCR2CX3CR1HTR1BCXCR1CCR7 | |
| SCHEMBL2905264 | 0.76 | CXCR2 (0.71) | CXCR2CX3CR1HTR1BCXCR1CCR7 | |
| SCHEMBL842340 | 0.76 | CXCR2 (0.71) | CXCR2CX3CR1HTR1BCXCR1CCR7 | |
| SCHEMBL841856 | 0.76 | CXCR2 (0.65) | CXCR2CX3CR1HTR1BCXCR1 | |
| SCHEMBL4693395 | 0.76 | CXCR2 (0.70) | CXCR2CX3CR1HTR1BCXCR1CCR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090239882-A1 | Thiazolopyramidine Compounds for the Modulation of Chemokine Receptor Activity | ASTRAZENECA AB (SE) | 2009-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239882-A1 | Thiazolopyramidine Compounds for the Modulation of Chemokine Receptor Activity | ACKR3, CXCR1, CCL11 | CXCR2 5/4885CX3CR1 11/4885HTR1B 2606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.